This session provides a detailed look at how structured, risk‑stratified active surveillance can be embedded into routine prostate cancer care, using lessons learned from the STRATCANS approach and its implementation across different NHS settings. As active surveillance becomes increasingly central to managing low‑risk prostate cancer, secondary care teams need clear, practical strategies to ensure pathways are consistent, evidence‑based, and responsive to patient needs.
Andrew Seggie will outline the evidence base underpinning risk‑stratified active surveillance, drawing on his work leading national research and consensus development at Prostate Cancer UK. He will discuss how structured protocols can support earlier diagnosis, reduce variation, and drive meaningful practice change.
Building on this, Uro‑Oncology Clinical Nurse Specialists Samantha McBeigh and Claire Turner will share their extensive experience developing and delivering nurse‑led services, including biopsy pathways, follow‑up clinics, and supported self‑management models. They will explore the central role of CNS leadership in implementing new approaches, the importance of communication and collaboration across departments, and the practical challenges encountered when redesigning services — from workforce capacity to patient engagement.
The session will also highlight how patient voice and lived experience can shape more effective and acceptable surveillance pathways, ensuring that services remain person‑centred while meeting operational and clinical demands. Designed for secondary care clinicians, this session forms part of the Specialists Conference 2026 and offers actionable insights for teams seeking to modernise and optimise their active surveillance pathways.


